Drug intelligence / Profile preview

MSLNAMA-CD3AMG

Development stage: Unknown

Overview

MSLNAMA-CD3AMG is an experimental compound that has demonstrated in vivo efficacy in preclinical patient-derived xenograft models, specifically inducing complete remission in the NTPL-146 and DF-5 models[2][4]. No detailed mechanism of action, pharmacokinetics, clinical indication, or developer information is available from the provided sources.

Targets

CD3 (T-cell surface glycoprotein CD3)Mesothelin

Beyond the preview

Go deeper on MSLNAMA-CD3AMG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSLNAMA-CD3AMG.

Explore the full profile